论文部分内容阅读
目的:评价丝裂霉素膀胱内热灌注(43~44℃)疗法对膀胱癌患者症状缓解和免疫功能的影响。方法:选取2011年3月—2013年10月间收治的膀胱癌患者68例,采用随机分组法将其分为常温灌注组和热灌注组,每组34例;常温灌注组患者在经尿道电切术后给予丝裂霉素膀胱内常温灌注治疗,热灌注组患者在经尿道电切术后给予丝裂霉素膀胱内热灌注治疗;比较两组患者治疗后膀胱癌症状的缓解率、3年后的复发率以及治疗前后免疫功能各指标的测得值。结果:热灌注组患者治疗后膀胱癌症状缓解率高于常温灌注组(P<0.05),治疗3年的复发率低于常温灌注组(P<0.05);两组患者治疗前免疫功能各指标经组间比较其差异无统计学意义(P>0.05);治疗后热灌注组患者的免疫功能各指标均优于常温灌注组(P<0.05)。结论:采用经尿道电切术后丝裂霉素膀胱内热灌注治疗膀胱癌患者,可有效缓解其症状,改善了免疫功能,降低了复发率。
Objective: To evaluate the effect of intravesical mitomycin (43 ~ 44 ℃) therapy on symptom relief and immune function in patients with bladder cancer. Methods: Sixty-eight patients with bladder cancer who were admitted between March 2011 and October 2013 were randomly divided into normal temperature group and heat perfusion group, 34 patients in each group. Patients in normal temperature group received transurethral electrovaporization Mitomycin was given intrauterine instillation at normal temperature after the operation. The patients in the heat perfusion group were treated with intravesical intravesical instillation of mitomycin C after transurethral resection of the bladder. The response rate of bladder cancer after treatment was compared between the two groups for 3 years After the recurrence rate and the immune function before and after treatment of the measured values of various indicators. Results: The remission rate of bladder cancer after heat perfusion group was higher than that of normal temperature perfusion group (P <0.05), and the recurrence rate of 3-year treatment group was lower than that of normal temperature perfusion group (P <0.05). The immune function indexes There was no significant difference between the two groups (P> 0.05). After treatment, the indexes of immune function in the heat perfusion group were better than those in the normal temperature perfusion group (P <0.05). Conclusion: The treatment of bladder cancer with intravesical instillation of mitomycin after transurethral resection of the bladder can effectively relieve the symptoms, improve the immune function and reduce the recurrence rate.